Nivolumab-Associated Pulmonary and Bone Sarcoidosis in a Patient With Melanoma of Unknown Primary. (September 2019)

• Record Type: Journal Article
• Authors: Tulbah, Rima I.; Rowe, Steven P.; Solnes, Lilja B.; Javadi, Mehrbod S.
• Is Part Of: Clinical nuclear medicine. Volume 44:Number 9(2019)
• Publication Date: 2019-09
• Subjects: malignant melanoma -- nivolumab -- osseous sarcoidosis -- pulmonary sarcoidosis; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000002724
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: A 57-year-old man with stage IIIB malignant melanoma of unknown primary presented for pretherapy FDG PET/CT that demonstrated metastatic left cervical lymph node with no other site of involvement. Following left neck dissection, nivolumab was initiated. Follow-up FDG PET/CT 3 months after initiation of nivolumab demonstrated extensive radiotracer-avid chest lymphadenopathy and multiple bone lesions. Ultrasound-guided endobronchial biopsy of the mediastinal lymph nodes demonstrated sarcoidosis.